TALAPRO-2

Study Type:
Interventional[Clinical Trial]

Study Design:

  • Interventional Model: Parallel Assignment
  • Intervention Model Description: To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
  • Estimated Enrollment: 1037 participants
  • Masking: Double-blind
  • Primary Purpose: Treatment
  • Official Title:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer